Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
IMbrave151
A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer
- NCT04677504 ↗
- Completed
- Hoffmann-La Roche
- Deep
We haven't built an HCP commentary report on IMbrave151 (atezolizumab plus bevacizumab in untreated advanced biliary tract cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on IMbrave151 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 28 | |
| YouTube | 1 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase II, Randomized, Double-Blind Placebo-Controlled Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Biliary Tract Cancer
- Interventions
- Atezolizumab; Bevacizumab; Placebo; Cisplatin; Gemcitabine
- Arms
- Arm A: Atezo+Bev+CisGem, followed by Atezo+Bev · Experimental
- Arm B: Atezo+PBO+CisGem, followed by Atezo+PBO · Active comparator
- Enrollment
- 162
- Primary outcomes
- Progression Free Survival (PFS)
- Sponsor
- Hoffmann-La Roche
- Start
- Feb 23, 2021
- Primary completion
- May 16, 2022
- Results posted
- Yes
- Registry record
- NCT04677504 · updated Jul 3, 2024
Publications
linked from the registry- Macarulla T, Ren Z, Chon HJ, Park JO, Kim JW, Pressiani T, Li D, Zhukova L, Zhu AX, Chen MH, Hack SP, Wu S, Liu B, Guan X, Lu S, Wang Y, El-Khoueiry AB. Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial. J Clin Oncol. 2025 Feb 10;43(5):545-557. doi: 10.1200/JCO.24.00337. Epub 2024 Oct 18. PubMed 39423355
- Hack SP, Verret W, Mulla S, Liu B, Wang Y, Macarulla T, Ren Z, El-Khoueiry AB, Zhu AX. IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. Ther Adv Med Oncol. 2021 Jul 31;13:17588359211036544. doi: 10.1177/17588359211036544. eCollection 2021. PubMed 34377158